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Tamoxifen elicits atheroprotective action through the AF- 1 of ERalpha 
but does not accelerate reendothelialization.
Coralie Fontaine (1), Audrey Billon- Galès (1), Anne Abot [Orateur] (1), 
Gilles Flouriot (2), Hortense Berges (1), Jean- François Arnal (1)
(1) I2MC, Equipe 9, U1048, Toulouse, France - (2) Université de Rennes 
I, Centre National de la Recherche Scienti¿ que (CNRS), Rennes, France
Objective: Estrogens, and in particular 17b- estradiol, activate the Estrogen 
Receptor (ER)s and induce gene transcription through two distinct activation 
functions (AF- 1 and AF- 2). The “selective” ER modulator tamoxifen, known 
as an AF- 1 agonist/AF- 2 antagonist in vitro, decreases the recurrence risk
of ERa- positive breast cancer, whereas it mimics part of the actions of estro-
gens on uterus, bone and vessels. The goal of the present work is to delineate 
the vascular effects of tamoxifen as well as its molecular target(s) in vivo.
Methods and Results: 1) We extend to ovariectomized Low Density 
Lipoprotein receptor de¿ cient mice (LDL- r- /- ) the atheroprotective action of 
tamoxifen, 2) but, in contrast to 17b- estradiol, tamoxifen fails to accelerate
reendothelialization after carotid electric injury. 3) The atheroprotective 
action of tamoxifen is abrogated in ERα- /- LDL- r- /- mice. 4) Tamoxifen diffe-
rently alters aortic gene expression as compared to 17b- estradiol. 5) Finally, 
the atheroprotective effect of tamoxifen, as well as its uterotrophic action, is 
abrogated in LDL- r- /- mice selectively de¿ cient in ERαAF- 1.
Conclusions: We demonstrate for the ¿ rst time that tamoxifen mediates 
most of its actions in vivo through the selective activation of ERαAF- 1, which 
is suf¿ cient to prevent atheroma, but not to accelerate endothelial healing.
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Does the coronary anatomy predicts outcomes after PCI of Unprotected 
Left Main Coronary Artery? 
Florent Laveau [Orateur], Olivier Barthelemy, Emmanuel Berman, G. Helft, 
J. Silvain, R. Choussat, F. Beygui, Jean Philippe Collet, Pierre Louis Michel, 
G. Montalescot, C. Le Feuvre
CHU Pitié Salpêtrière, Département de Cardiologie Médicale, Paris Cedex 
13, France
Aims: To assess one year clinical outcomes according to coronary anatomy 
(Number of vessels diseased, Syntax score) after unprotected left main (LM) 
coronary artery (ULMCA) PCI in an unselected patients population. 
Methods: Consecutive patients treated by PCI for ULMCA were included 
among a single center 3508 PCI database within 36 months. Syntax scores 
and one year clinical outcomes (Death, TVR, MACCE=cardiovascular 
death+MI+stroke+TLR) were recorded.
Results: 102 (3.6%) patients underwent PCI of the LM, including 21 pro-
tected LM. Among the 81 patients with PCI of ULMCA, 23(28%), 22(27%), 
20(25%) and 16(20%) had LM only, LM+1 vessel, LM+2 vessels, LM+3 
vessels disease, respectively. Mean age was 65±13, 25% had diabetes, 27% 
had urgent PCI for AMI, cardiogenic shock or OHCA, 61% had DES. 
SYNTAX score was 28±14 in mean and was 22 in 30 (37%), 23 to 32 in 
22 (27%) and >32 in 29 (36%) patients.
At 12 months, follow up was completed for 98% of the patients. Events 
were frequent in this high risk population with death occurring in 15 patients 
(18.5%), TVR in 11 (14%) and MACCE in 24 (30%). 
Clinical events according to the number of vessels diseased and the Syntax 
score are shown in ¿ gure 1.
MACCE rates were signi¿ cantly lower when DES were used (15% vs. 
52%, p<0.05) and in case of non- urgent PCI (17% vs. 64%, p<0.05).
Conclusions: In unselected patients treated by PCI of ULMCA, one- 
year outcome was found to be excellent in patients with Syntax score 22 
(more than one third of the population), and acceptable in patients with iso-
lated LM disease. DES and non- urgent PCI were associated with a better 
prognosis.
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M1 and M2 macrophages expression pro¿ les in human atherosclerosis 
and modulation by cardiovascular risk factors
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Stephan Haulon (2), Giulia Chinetti (3), Bart Staels (3), Brigitte Jude (1), 
Annabelle Dupont (1)
(1) Univ Lille Nord de France, UDSL, IFR 114, EA 2693, faculté de 
Médecine pole recherche, Lille Cedex, France - (2) CHRU Lille, Pôle de 
Cardiologie et Chirurgie Cardiovasculaire, Lille, France - (3) INSERM 
U1011, Institut Pasteur de Lille, Lille, France
Atherosclerosis is characterized by chronic inÀ ammation associated with 
macrophage in¿ ltration in arterial intima. Two macrophages subpopulations, 
M1 and M2, coexist in human atherosclerotic plaques and release a variety 
of mediators such as pro/anti- inÀ ammatory cytokines, Tissue Factor (TF), 
the primary initiator of the coagulation cascade and its major physiological 
inhibitor, the Tissue Factor Pathway Inhibitor (TFPI), pro- angiogenic factors 
(VEGF, Vascular Endothelium Growth Factor) and matrix metalloproteinases 
(MMP) involved in plaque vulnerability. 
We aimed at comparing the expression levels of these mediators between 
M1 and M2 circulating monocytes derived macrophages (MDM) from athero-
sclerotic patients and then, evaluating the impact of major cardiovascular risk 
factors on these expression pro¿ les. 
MDM from 22 atherosclerotic patients were cultured with IL- 1β (10 ng/
ml) and IL- 4 (10 ng/ml) to induce M1 and M2 phenotype, respectively. The 
atherosclerotic mediators’ expression pro¿ les were evaluated by quantitative 
RT- PCR. 
In this study, we con¿ rmed the pro- inÀ ammatory proprieties of M1 
(increased expression of TNFα and IL- 6) and anti- inÀ ammatory capacities of 
M2 (increased expression of IL- 10). We observed that M1 were anti¿ brinolytic 
(signi¿ cantly increased expression of PAI- 1, Plasminogen Activator Inhibitor- 1, 
¿ brinolysis inhibitor, in M1 vs M2, p=0.016) and signi¿ cantly expressed more 
MMP- 9 (p<0.0001). Concerning M2, they present a signi¿ cantly increased 
expression of VEGF (p=0.05) and TFPI (p=0.011), modulating plaque insta-
bility and thrombogenicity. Moreover, we observed a signi¿ cant inÀ uence of 
diabetes and age on macrophages expression pro¿ les. Indeed, diabetic patients 
present a more important proangiogenic activity in M1 that could explain the 
higher fragility of plaques currently observed in these patients.
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Drug eluting Stent in Elderly patients: The real life
Rania Hammami [Orateur], Leila Abid, Souad Mallek, Dorra Abid, Malek 
Akrout, Feten Triki, Mourad Hentati, Samir Kammoun
Service de Cardiologie de Sfax - Tunisie, Sfax, Tunisie
Purpose: Drug- eluting stents (DES) have markedly reduced the incidence 
of restenosis as compared with bare- metal stents.
However, the prolonged duration of dual anti- platelet therapy, make their 
use more restricted in eldery patients. 
The aim of our study was to evaluate the safety of drug eluting stents in 
the elderly.
Patients and methods: This is a retrospective study including 619 patients 
undergoing angioplasty with 802 DES. We compared two groups: Group1=age 
70 years (143 patients); Group 2=age <70 years (476 patients).
Results: There was no difference between the 2 groups regarding cardio-
vascular risk factors including diabetes (p=0.12). Unstable angina was the 
most frequent clinical event in elderly patients (48%). Three- vessel disease 
was found more often than in younger patients (G1=30.2%, G2=20.9%, 
p=0.003). The main site of implantation of drug- eluting stent in more 
elderly patients is left anterior descending coronary (G1=78.3%, G2=69.2%, 
p=0.04). There was no signi¿ cant difference between the 2 groups regar-
ding the procedural success or the occurrence of in- stent restenosis (p=0.74). 
The occurrence of stent thrombosis was more frequent among elderly patients 
(G1=6.9%, G2=2.9%, p=0.06). However, there was no difference regarding the 
duration of plavix or the occurrence of bleeding complications (p=0.21).
Conclusion: Covered stents in our population seem to be secure even in 
the elderly, but the interrogatory and the physical examination must be precise 
in this population because of increased risk of bleeding and surgical gestures 
more frequent.
0060
InÀ uence of gender on one- year clinical outcomes after Drug Eluting 
Stent implantation compared to Bare Metal Stent
Aude Healy- Brucker [Orateur], Anne Bellemain- Appaix, Olivier 
Barthelemy, Pierre- Louis Michel, Johanne Silvain, Farzin Beygui, Jean- 
Philippe Collet, Emmanuel Berman, Gilles Montalescot, Claude Lefeuvre
Hôpital Pitié- Salpêtrière, Cardiologie, Paris, France
Background: Women with coronary artery disease have a higher morta-
lity rate than men, especially after percutaneous coronary intervention (PCI). 
The impact of drug- eluting stent (DES) vs. bare metal stent (BMS) on this 
¿ nding is unknown. 
Aim: To compare one year safety and effectiveness of DES vs. BMS in all 
comers PCI according to sex. 
Methods: Patients were divided in 4 groups, according to stent used (DES 
vs. BMS) and sex (women vs. men). Clinical and angiographic data were 
prospectively entered into the “Middle- Care” database. The occurrence of car-
diovascular (CV) death, Major Adverse Clinical Event (MACE), TLR and 
stent thrombosis (ST) was recorded at one year follow- up. 
Results: 2794 patients underwent PCI with stent implantation. 21.1% were 
women, and 47.8% of stents were DES. Women were older (68.9±12.9 year 
vs. 64.0±12.1 year, p<0.0001), had more renal dysfunction (42.8% vs. 22.5%, 
p<0.0001), a trend for more hypertension (65.4% vs. 56.4%). Women pre-
sented more frequent cardiogenic shock than men (4.8% vs. 2.7%, p=0.01), 
less frequent radial access (82.2% vs. 88.8%, p<0.0001), and shorter total 
length of stent implanted (25.8 vs. 27.2mm, ns). CV death was higher in 
women than in men (8.9% vs. 6.2%, p=0.02) with a higher trend for more all 
cause death (11.1% vs. 9.6% p=0.08) and MACE (13.1% vs. 11.5%, p=0.03). 
There is no difference between genders in CV death in the BMS group (13.7% 
vs. 10.7%, ns), nor in the DES group (3.6% vs. 2.2%) ; similar ¿ ndings were 
found for all cause of death (17.3% vs. 14.6%, p=0.7) and for MACE (19%vs 
15.2%, p=0.6). There are bene¿ ts of DES over BMS implantation, but no dif-
ference between male and female (¿ gure 1).
Conclusions: Mortality is higher in women when compared to men after 
PCI. 
DES implantation showed bests results than BMS for male and female and 
there is no difference between the gender.
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Microparticles isolated from human atherosclerotic plaque promote 
macrophage transformation into foam cells
Min Yin [Orateur] (1), Sophie Pégorier (1), Pierre Julia (2), Alain Tedgui (1), 
Chantal Boulanger (1)
(1) inserm u970, Equipe 1, Paris, France - (2) Hôpital Européen Georges 
Pompidou, Service de Chirurgie vasculaire, Paris, France
Background: Microparticles (MPs) are 0.1- 1μm membrane- shed vesicles 
released following cell activation/apoptosis. They accumulate in atherosclerotic 
lesions where they promote inÀ ammation and angiogenesis. Monocyte transfor-
mation into foam cells by subendothelial modi¿ ed- or oxidized- LDL is central 
to atherosclerotic lesion development. Little is known about how MPs interact 
with macrophages (Mac). We aimed to evaluate the effect of MPs isolated from 
human atherosclerotic plaques (PMPs) on monocyte/Mac activation.
Methods: PMPs were isolated from 10 human endoarterectemy lesions 
as described before. PMA- induced adherent U937 cells and human mono-
cytes isolated from healthy volunteers (¿ coll gradient and CD14+ selection) 
were incubated for 1- 7 days with vehicle or 6000 AnnV+PMPs/l, a level 
consistent with local MP concentration in plaques. ABCA1, LXRa and LDLR 
expressions were analyzed by QPCR and western blot; cytokine release was 
quanti¿ ed by Elisa. Cell survival/proliferation and H2O2 production were 
assessed using WST- 1 cell proliferation and PeroXOquant assays, respectively.
Results: PMPs increased Mac and U937 survival/proliferation by 1.5 and 5 
fold at day 7, respectively. Interestingly, CFSE+PMPs were already detected in 
Mac cytoplasm at 30min. PMP uptake was associated with lipid droplet accumu-
lation that increased with time and lasted for 7 days. PMP exposure for 7 days 
increased ABCA1 mRNA and protein (4 and 2.5 fold) and LXRa transcript levels 
(3 fold) when compared to vehicle. However PMPs inhibited LDLR protein 
expression by 2 as well as IL- 6 and H2O2 releases by 1.5 and 2 respectively.
Conclusion: PMP uptake increases Mac survival/proliferation, contributes 
to the establishment of an equilibrium between lipid accumulation and choles-
terol recycling and promotes a foam cell- like phenotype. In conclusion PMPs 
may protect Mac from excessive lipid accumulation, contribute to increase 
plaque cellularity and therefore its progression.
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